triazoles has been researched along with Lymphoma, T-Cell, Cutaneous in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, Y; Kamijo, H; Miyagaki, T; Oka, T; Sato, S; Sugaya, M; Takahashi, N | 1 |
| Chen, WT; Chen, YC; Hsiao, CH; Hsueh, PR; Ko, BS; Kuo, YM; Liu, JY; Yao, M | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
1 review(s) available for triazoles and Lymphoma, T-Cell, Cutaneous
| Article | Year |
|---|---|
Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review.
Topics: Adult; Alemtuzumab; Amphotericin B; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Agents; Combined Modality Therapy; Deoxycholic Acid; Drug Combinations; Drug Therapy, Combination; Fever; Fusariosis; Fusarium; Granulocytes; Humans; Immunocompromised Host; Leukocyte Transfusion; Lymphoma, T-Cell, Cutaneous; Male; Microbial Sensitivity Tests; Neutropenia; Pyrimidines; Skin Neoplasms; Triazoles; Voriconazole | 2011 |
2 other study(ies) available for triazoles and Lymphoma, T-Cell, Cutaneous
| Article | Year |
|---|---|
BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
Topics: Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Humans; Interleukin-2 Receptor alpha Subunit; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Mice, SCID; Nuclear Proteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Receptors, CCR4; RNA-Binding Proteins; RNA, Messenger; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |